ICYMI: New Report on Benefits of Cancer Medicines That Emerge After FDA Approval

In case you missed it, Boston Healthcare Associates recently published a report examining how additional benefits of cancer medicines emerge over time through ongoing research after initial...
Read More
ASCO’s Framework: Value at the Crossroads

Yesterday the American Society of Clinical Oncology (ASCO) released its long-awaited draft conceptual framework to assess the value of cancer treatment options. PhRMA has long supported the...
Read More